// COMPANY
Rallybio
SECTOR BIOTECHMENTIONS 1LAST SEEN MAY 4, 2026
// OVERVIEW
Biotech company that had a reverse merger agreement with Candid Therapeutics before losing the deal to UCB.
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
mention·Axios Pro Rata·MAY 4, 2026
“Candid had previously agreed to a reverse merger with Rallybio, but says that UCB made a superior offer.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.